<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03853005</url>
  </required_header>
  <id_info>
    <org_study_id>28503011700371A1</org_study_id>
    <nct_id>NCT03853005</nct_id>
  </id_info>
  <brief_title>Effect of High volumeHemodiafiltration on Lung Oxygenation and Mechanics</brief_title>
  <official_title>Effect of High Volume Hemodiafiltration on Lung Oxygenation, Lung Mechanics and Biomarkers in Mechanically Ventilated Patients With Severe Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate improvement of sepsis patients with a new modality of treatment (HDF)
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 15, 2019</start_date>
  <completion_date type="Anticipated">April 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arterial oxygen pressure</measure>
    <time_frame>at 0 hour, 24hours and after completion of 48 hours</time_frame>
    <description>change in arterial oxygen pressure (PO2) in units of millimeter mercury (mmHg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>lung mechanics</measure>
    <time_frame>0, 24, and 48 hours</time_frame>
    <description>change in compliance (ml/cmH2O)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory biomarkers</measure>
    <time_frame>0, 24, and 48 hours</time_frame>
    <description>Measure inflammatory biomarkers: Interleukin-6.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Haemofiltration</condition>
  <condition>Lung Mechanics</condition>
  <condition>Septic Patients</condition>
  <arm_group>
    <arm_group_label>Group A (controlled group)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>They will not receive HVHDF treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (HVHDF group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>They will receive HVHDF treatment for at least 48 hours. HVHDF will be performed via indwelling central venous catheter. The blood flow will be 180-240 ml/min, and ultrafiltration rate will be 35-50 ml/kg/h during HVHF. The substitute fluid will be infused with pre-dilution. Heparin will be used for anti-coagulation, whose initial dose will be 15-25 U/kg, and maintenance dose is 5-15 U/kg/h. aPTT time maintained between 60-80 second and will be checked every 12 hours. The survival status of all of the subjects were followed up at 28 days after being diagnosed as severe sepsis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HVHDF</intervention_name>
    <description>Patients will receive HVHDF treatment for at least 48 hours. HVHDF will be performed via indwelling central venous catheter. The blood flow will be 180-240 ml/min, and ultrafiltration rate will be 35-50 ml/kg/h during HVHF. The substitute fluid will be infused with pre-dilution. Heparin will be used for anti-coagulation, whose initial dose will be 15-25 U/kg, and maintenance dose is 5-15 U/kg/h. aPTT time maintained between 60-80 second and will be checked every 12 hours.</description>
    <arm_group_label>Group B (HVHDF group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>controlled</intervention_name>
    <description>supportive care</description>
    <arm_group_label>Group A (controlled group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥ 18 years

          2. Severe sepsis defined by Quick SOFA score by presentation of 2 or more of the
             following criteria:

               -  Mental clouding: decreased glasco coma scale GCS &lt; 15

               -  Hypotension: Systolic blood pressure &lt; 100 mmgH

               -  Tachypnea: respiratory rate &gt; 22 breath/ minute Then serum lactate is analysed to
                  confirm sepsis hypoperfusion if ≥ 2mmol/L

          3. Organs dysfunction (including one of them respiratory failure).

        Organ dysfunctions are defined as following:

        Respiratory dysfunction (criteria for ARDS):

          -  PaO2/FiO2 &lt;200

          -  Bilateral infiltrates in chest X-ray

          -  Resistant hypoxemia

          -  Tachypnoea (RR &gt; 40 breath/minute)

          -  The need for invasive mechanical ventilation

          -  Excluded cardiac causes of pulmonary edema

        CNS failure:

          -  Decreased GCS ≥ 4 decreased points

        CVS dysfunction:

          -  Sustained hypotension even on very high inotropes doses (Noradrenaline &gt;1µm/min)+
             adrenaline&gt;1.5µm/min associated

          -  with high CVP pressure &gt; 12 mmHg and not responding to fluid challenge test to exclude
             hypovolemia.

          -  Cardiomegaly detected by either echocardiography assessment, or chest X-ray

          -  Resistant frequent ventricular ectopics not explained by organic causes.

        Liver dysfunction:

          -  Elevated total and direct bilirubin than double normal or basal levels

          -  Elevated prothrombin time &gt; 17 seconds or INR &gt; 1.5

          -  Elevated liver enzymes &gt; triple normal level

        Renal dysfunction:

          -  Decreased urine output &lt; 0.5 ml/kg.

          -  Elevated creatinine level &gt; 164 µmol/L (1.5mg/dL).

          -  Decreased creatinine clearance &lt;50ml/minute if available.

        Bone marrow depression:

          -  Decreased platelets &lt; 90 X 103/µL

          -  Decreased leukocytes &lt;4 X 103/µL

          -  Decreased RBCs count &lt; 4 X 106/µL

        Exclusion Criteria:

          1. Patient relatives' refusal

          2. Pregnancy

          3. Recent active internal hemorrhage

          4. Not mechanically ventilated.

          5. Hypersensitivity to the dialyser fluid
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Assiut university A Egypt</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ayman A Glala, Ass.lecturer</last_name>
    <phone>00201025675901</phone>
    <email>Aymanglala24@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abdelrady I Shehata, professor</last_name>
    <phone>00201026249924</phone>
    <email>aradys2000@yahoo.com</email>
  </overall_contact_backup>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>July 10, 2018</study_first_submitted>
  <study_first_submitted_qc>February 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2019</study_first_posted>
  <last_update_submitted>March 10, 2019</last_update_submitted>
  <last_update_submitted_qc>March 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ayman Abd El-Khalek Mohammed Glala</investigator_full_name>
    <investigator_title>Ayman Abd ELkhalek Mohammed, assistant lecturer, clinical anesthesiologist and principal investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

